LAURA WALLS: Open Payments
NPI 1497192595 · GOLDEN, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$347 in 16 payments from 8 companies in 2025. Trend: 2023 $18 · 2024 $0 · 2025 $347
Food & beverage: $347
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $118 |
| Novo Nordisk Inc | 4 | $81 |
| Janssen Pharmaceuticals, Inc | 2 | $35 |
| Gilead Sciences, Inc. | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $15 |
Products named: VRAYLAR, SPRAVATO, Ozempic, UBRELVY, QULIPTA, Wegovy, REXULTI, VAXELIS.
Industry payments across CO — which companies pay providers there.
